Many big pharmaceutical companies managed to weather the recent flurry of patent expirations that affected their top lines. Merck (MRK 0.18%), a Dow component and one of the planet's largest drugmakers, was hit hard by the loss of exclusivity for its multibillion-dollar drug Singulair, and it now relies on blockbuster drugs Januvia and Janumet. But will the big pharma have to deal with more patent expirations in the coming years? In the following video, analysts David Williamson and Max Macaluso focus on the drugs that Merck stands to lose protection on in the coming years.
Time to Panic About Merck's Patent Expirations?
By Max Macaluso and Dave Williamson – Sep 27, 2013 at 11:55AM
NYSE: MRK
Merck
Market Cap
$217B
Today's Change
(-0.18%) $0.16
Current Price
$86.87
Price as of October 29, 2025 at 11:43 AM ET
A look at which products Merck will lose patent protection on in the coming years.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo